Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg...
| Auteurs principaux: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Publié: |
Future Medicine
2019
|
| Sujets: |